Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano Sanna, Ph.D., as Chief Executive Officer and President. Dr. Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the Interim CEO and will remain as an advisor to the Company.
“Bastiano has the perfect set of skills and experiences to lead Semma through our next phase of growth as a company after a very successful Series B financing,” said Mark Fishman, M.D., Chairman of Semma’s Board of Directors. “Few leaders have such a strong cell therapy background combined with his level of strategic and business experience.”Back to News